Table 6.
The Impact of E484K on Neutralization of Monoclonal Antibodies Under Phase III Clinical Trial
| Drug | Developer | Status | Trial ID | The Impact of E484K on Neutralization |
|---|---|---|---|---|
| Bamlanivimab and etesevimab | Eli Lilly and Company | EUA | NCT04427501 (Phase 2/3) | Reduced by 17-fold49 |
| REGN-COV2 (casirivimab and imdevimab) | Regeneron Pharmaceuticals | EUA | NCT04452318 | No change15,49,51 |
| Sotrovimab (VIR-7831/GSK4182136) | Vir Biotechnology Inc and GlaxoSmithKline | PhaseII/III clinical trials | NCT04545060 | No change53 |
| AZD7442 (AZD8895 and AZD1061) | AstraZeneca | Phase I; phase III pending |
NCT04507256 (phase 1) NCT04625725 (phase 3) NCT04625972 (phase 3) |
Minor reduction15,55,60 |
| TY027 | Tychan Pte Ltd | Phase I; phase III pending | NCT04429529 NCT04649515 | No data |
| Regdanvimab (CT-P59) | Celltrion | Phase 3 clinical trials | NCT04525079 | 2-fold against E484K57 |